Goldman Sachs’s Halozyme HALO Stock Holding History

Goldman Sachs’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60,000	Closed	-$2.5M	–	6335
2021 Q1	$2.5M	Buy	+60,000	New	+$2.74M	﹤0.01%	3764
2016 Q2	–	Sell	-50,000	Closed	-$474K	–	7111
2016 Q1	$474K	Hold	50,000	–	–	﹤0.01%	4788
2015 Q4	$866K	Buy	+50,000	New	+$797K	﹤0.01%	4440
2015 Q1	–	Sell	-75,000	Closed	-$724K	–	7162
2014 Q4	$724K	Buy	+75,000	New	+$666K	﹤0.01%	4909
2014 Q2	–	Sell	-98,500	Closed	-$1.25M	–	7058
2014 Q1	$1.25M	Buy	+98,500	New	+$1.46M	﹤0.01%	4445

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Goldman Sachs's HALO Position: Q2 2026 in Review

Goldman Sachs increased its Halozyme (HALO) stake by 74% in Q2 2026, buying an estimated $36.8M and bringing the position to 1,270,344 shares worth $99.4M. The position accounts for 0.01% of the portfolio, ranked #1229.

Goldman Sachs first reported a position in HALO in Q2 2013 and has held it in 53 quarters since. The position peaked at $113M in Q4 2022. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Goldman Sachs held 1,270,344 shares of Halozyme worth $99.4M as of Q2 2026.
Goldman Sachs bought 540,204 Halozyme shares in Q2 2026, an estimated $36.8M.
Halozyme made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1229 holding.
Goldman Sachs first reported a position in Halozyme in Q2 2013 and has held it in 53 quarters since.
Goldman Sachs's Halozyme position peaked at $113M in Q4 2022.
672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.